Amphastar Pharma (AMPH) Misses Q3 EPS by 4c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.96, $0.04 worse than the analyst estimate of $1.00. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $194.69 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral